News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
EDDING GENOR (06998.HK) Partner Candid Therapeutics to Be Acquired by UCB
EDDING GENOR (06998.HK) announced that Belgian pharmaceutical group Union Chimique Belge (UCB) will acquire Candid Therapeutics. Under the terms of the agreement, UCB will pay an u...
Reset
Send
The window will close in 5 seconds
EDDING GENOR (06998.HK) Partner Candid Therapeutics to Be Acquired by UCB
Close
Recommend
5
Positive
9
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

EDDING GENOR (06998.HK)  -0.070 (-3.500%)    Short selling $80.46K; Ratio 4.204%   announced that Belgian pharmaceutical group Union Chimique Belge (UCB) will acquire Candid Therapeutics. Under the terms of the agreement, UCB will pay an upfront payment of USD2 billion, together with up to USD200 million in potential future milestone payments. The acquisition is expected to be completed between the end of 2Q26 and early 3Q26.

Under the revised agreement, the Group and Candid Therapeutics will jointly advance the clinical development of GB261 in the field of autoimmune diseases. Multiple clinical studies, including those for rheumatoid arthritis and systemic lupus erythematosus, have already been initiated, continuously expanding its therapeutic application scenarios.

In 2024, Candid Therapeutics merged with TRC 2004, Inc. The global exclusive license rights for GB261 previously granted by the Group to TRC 2004, Inc. were transferred to Candid Therapeutics, while the Groups equity interest in TRC 2004, Inc. was converted into an equity stake in Candid Therapeutics. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-01 12:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.